Maia Biotechnology
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC (NCT06908304) | Maia Biotechnology | 2025-12-08 |
| THIO Sequenced With Cemiplimab in Advanced NSCLC (NCT05208944) | Maia Biotechnology | 2022-06-08 |
Track Maia Biotechnology automatically
Every clearance here is in the API, with alerts when new ones post.